BRPI0816326A2 - Compostos que modulam cálcio intracelular - Google Patents

Compostos que modulam cálcio intracelular

Info

Publication number: BRPI0816326A2
Authority: BR; Brazil
Prior art keywords: compounds; intracellular calcium; modulate intracellular; modulate; calcium
Prior art date: 2007-09-10

Application number

Other languages

English (en)

Inventor

Gonul Velicelebi

Kenneth A Stauderman

David P M Pleynet

Soan Cheng

Jeffrey P Whitten

Original Assignee

Calcimedica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-09-10

Filing date

2008-08-15

Publication date

2015-03-24

2008-08-15 Application filed by Calcimedica Inc filed Critical Calcimedica Inc

2015-03-24 Publication of BRPI0816326A2 publication Critical patent/BRPI0816326A2/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
- C07D333/62—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
- C07D333/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physical Education & Sports Medicine (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Neurology (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Ophthalmology & Optometry (AREA)
Pain & Pain Management (AREA)
Gastroenterology & Hepatology (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Heart & Thoracic Surgery (AREA)
Gynecology & Obstetrics (AREA)
Reproductive Health (AREA)
Psychiatry (AREA)
Otolaryngology (AREA)

BRPI0816326 2007-09-10 2008-08-15 Compostos que modulam cálcio intracelular BRPI0816326A2 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US97116107P	2007-09-10	2007-09-10
PCT/US2008/073392 WO2009035818A1 (en)	2007-09-10	2008-08-15	Compounds that modulate intracellular calcium

Publications (1)

Publication Number	Publication Date
BRPI0816326A2 true BRPI0816326A2 (pt)	2015-03-24

Family

ID=40452397

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0816326 BRPI0816326A2 (pt)	2007-09-10	2008-08-15	Compostos que modulam cálcio intracelular

Country Status (11)

Country	Link
US (2)	US8263641B2 (pt)
EP (1)	EP2200607A4 (pt)
JP (1)	JP5411141B2 (pt)
KR (1)	KR101257550B1 (pt)
CN (1)	CN101854933A (pt)
AU (1)	AU2008299220B2 (pt)
BR (1)	BRPI0816326A2 (pt)
CA (1)	CA2699157A1 (pt)
MX (1)	MX2010002712A (pt)
RU (1)	RU2465272C2 (pt)
WO (1)	WO2009035818A1 (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2136820A4 (en) *	2007-03-05	2010-09-15	Univ Queensland	TARGET FOR BREAST CANCER THERAPY AND / OR DIAGNOSIS
JP5411141B2 (ja)	2007-09-10	2014-02-12	カルシメディカ，インク．	細胞内カルシウムを調節する化合物
WO2009076454A2 (en) *	2007-12-12	2009-06-18	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US7981925B2 (en)	2008-08-27	2011-07-19	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US8524763B2 (en)	2008-09-22	2013-09-03	Calcimedica, Inc.	Inhibitors of store operated calcium release
US8143269B2 (en) *	2008-10-03	2012-03-27	Calcimedica, Inc.	Inhibitors of store operated calcium release
US8618307B2 (en)	2009-09-16	2013-12-31	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US8377970B2 (en)	2009-10-08	2013-02-19	Rhizen Pharmaceuticals Sa	Modulators of calcium release-activated calcium channel
US8993612B2 (en)	2009-10-08	2015-03-31	Rhizen Pharmaceuticals Sa	Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer
SG10201501272SA (en)	2009-10-22	2015-04-29	Fibrotech Therapeutics Pty Ltd	Fused ring analogues of anti-fibrotic agents
CA2781532A1 (en)	2009-11-20	2011-05-26	Amgen Inc.	Anti-orai1 antigen binding protein that binds the second extracellular loop of orai1
US10703722B2 (en)	2010-04-27	2020-07-07	Calcimedica, Inc.	Compounds that modulate intracellular calcium
KR101799304B1 (ko)	2010-05-12	2017-11-20	렘펙스 파머수티클스 인코퍼레이티드	테트라사이클린 조성물
MX337711B (es)	2010-08-27	2016-03-15	Calcimedica Inc	Compuestos que modulan el calcio intracelular.
CN105566311A (zh)	2010-10-30	2016-05-11	印度鲁宾有限公司	噁唑及异噁唑钙释放激活的钙调节剂
CN102433383B (zh) *	2011-12-19	2015-07-08	上海吉凯基因化学技术有限公司	人stim1基因的用途及其相关药物
EP2844655A1 (en)	2012-05-02	2015-03-11	Lupin Limited	Substituted pyridine compounds as crac modulators
WO2013164773A1 (en)	2012-05-02	2013-11-07	Lupin Limited	Substituted pyrazole compounds as crac modulators
US9512116B2 (en)	2012-10-12	2016-12-06	Calcimedica, Inc.	Compounds that modulate intracellular calcium
EP2738172A1 (en)	2012-11-28	2014-06-04	Almirall, S.A.	New bicyclic compounds as crac channel modulators
WO2014203217A1 (en)	2013-06-21	2014-12-24	Lupin Limited	Substituted heterocyclic compounds as crac modulators
AU2014300629A1 (en)	2013-06-24	2015-12-24	Lupin Limited	Chromane and chromene derivatives and their use as CRAC modulators
EP2848615A1 (en)	2013-07-03	2015-03-18	Almirall, S.A.	New pyrazole derivatives as CRAC channel modulators
JP6399874B2 (ja) *	2013-09-20	2018-10-03	エーザイ・アール・アンド・ディー・マネジメント株式会社	化合物の抗炎症効果または免疫抑制効果を予測する方法
EP2982982B1 (en) *	2014-08-06	2017-10-04	Université de Bretagne Occidentale (U.B.O.)	Method of screening of compounds using membrane STIM1
JP6985146B2 (ja)	2015-02-27	2021-12-22	カルシメディカ，インク．	膵炎処置
EP3331525B1 (en)	2015-08-07	2020-10-07	Calcimedica, Inc.	Use of crac channel inhibitors for the treatment of stroke and traumatic brain injury
WO2018144620A1 (en)	2017-02-03	2018-08-09	Shire Human Genetic Therapies, Inc.	Anti-fibrotic compounds
CN108938625B (zh) *	2017-05-27	2021-06-29	北京大学	2-芳甲酰胺基噻吩-3-羧酸类衍生物作为ano1蛋白抑制剂的用途及制备方法
CN107496420B (zh) *	2017-08-25	2020-07-07	中国科学院微生物研究所	环匹阿尼酸类生物碱化合物的用途
EP3749649A1 (en) *	2018-02-08	2020-12-16	ENYO Pharma	Non-fused thiophene derivatives and their uses
WO2020053834A1 (en)	2018-09-14	2020-03-19	Rhizen Pharmaceuticals Sa	Compositions comprising a crac inhibitor and a corticosteroid and methods of use thereof
CN109081824A (zh) *	2018-10-08	2018-12-25	浙江工业大学上虞研究院有限公司	2-氨基噻吩类化合物的制备方法
EP4121089A4 (en)	2020-03-20	2024-04-10	Calcimedica, Inc.	METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACUTE LUNG LESION AND ACUTE RESPIRATORY DISTRESS SYNDROME
KR20240012344A (ko)	2020-11-13	2024-01-29	칼시메디카, 인크	Crac 채널 억제제의 개선된 합성
CN116444481B (zh) *	2022-01-05	2025-07-25	北京大学	作为ano1蛋白抑制剂的4-芳基噻吩甲酸类化合物
CN114948923A (zh) *	2022-06-02	2022-08-30	南京中医药大学	奥替溴铵及其盐在制备治疗周围神经病变以及肺纤维化药物中的应用

Family Cites Families (140)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3472802A (en)	1966-11-23	1969-10-14	Inter Chem Corp	Novel nitrocellulose flexographic printing inks
US3598123A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
US3993073A (en)	1969-04-01	1976-11-23	Alza Corporation	Novel drug delivery device
US3598122A (en)	1969-04-01	1971-08-10	Alza Corp	Bandage for administering drugs
ES371373A1 (es)	1969-09-10	1972-04-01	Patronato De Investigacion Cie	Procedimiento para la obtencion de derivados de 4-oxo-3- amino-3,4 - dihidrotieno (3,2-d) pirimidina sustituidos.
US3710795A (en)	1970-09-29	1973-01-16	Alza Corp	Drug-delivery device with stretched, rate-controlling membrane
US4069307A (en)	1970-10-01	1978-01-17	Alza Corporation	Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3731683A (en)	1971-06-04	1973-05-08	Alza Corp	Bandage for the controlled metering of topical drugs to the skin
US3742951A (en)	1971-08-09	1973-07-03	Alza Corp	Bandage for controlled release of vasodilators
US3996934A (en)	1971-08-09	1976-12-14	Alza Corporation	Medical bandage
BE795384A (fr)	1972-02-14	1973-08-13	Ici Ltd	Pansements
GB1419074A (en)	1972-06-09	1975-12-24	Ici Ltd	Process for manufacturing substituted thiophene compounds
US3921636A (en)	1973-01-15	1975-11-25	Alza Corp	Novel drug delivery device
US3993072A (en)	1974-08-28	1976-11-23	Alza Corporation	Microporous drug delivery device
US4151273A (en)	1974-10-31	1979-04-24	The Regents Of The University Of California	Increasing the absorption rate of insoluble drugs
US3972995A (en)	1975-04-14	1976-08-03	American Home Products Corporation	Dosage form
GB1548398A (en) *	1975-06-05	1979-07-11	Lilly Industries Ltd	Acylamino pyrroles furans and thiophenes
US4077407A (en)	1975-11-24	1978-03-07	Alza Corporation	Osmotic devices having composite walls
US4031894A (en)	1975-12-08	1977-06-28	Alza Corporation	Bandage for transdermally administering scopolamine to prevent nausea
US4060084A (en)	1976-09-07	1977-11-29	Alza Corporation	Method and therapeutic system for providing chemotherapy transdermally
US4201211A (en)	1977-07-12	1980-05-06	Alza Corporation	Therapeutic system for administering clonidine transdermally
JPS5562012A (en)	1978-11-06	1980-05-10	Teijin Ltd	Slow-releasing preparation
US4230105A (en)	1978-11-13	1980-10-28	Merck & Co., Inc.	Transdermal delivery of drugs
US4229447A (en)	1979-06-04	1980-10-21	American Home Products Corporation	Intraoral methods of using benzodiazepines
CA1146866A (en)	1979-07-05	1983-05-24	Yamanouchi Pharmaceutical Co. Ltd.	Process for the production of sustained release pharmaceutical composition of solid medical material
US4291015A (en)	1979-08-14	1981-09-22	Key Pharmaceuticals, Inc.	Polymeric diffusion matrix containing a vasodilator
US4327725A (en)	1980-11-25	1982-05-04	Alza Corporation	Osmotic device with hydrogel driving member
US5116817A (en)	1982-12-10	1992-05-26	Syntex (U.S.A.) Inc.	LHRH preparations for intranasal administration
US4476116A (en)	1982-12-10	1984-10-09	Syntex (U.S.A.) Inc.	Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
US4596795A (en)	1984-04-25	1986-06-24	The United States Of America As Represented By The Secretary, Dept. Of Health & Human Services	Administration of sex hormones in the form of hydrophilic cyclodextrin derivatives
US4624848A (en)	1984-05-10	1986-11-25	Ciba-Geigy Corporation	Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
GB8518301D0 (en)	1985-07-19	1985-08-29	Fujisawa Pharmaceutical Co	Hydrodynamically explosive systems
EP0230654B1 (en)	1985-12-28	1992-03-18	Sumitomo Pharmaceuticals Company, Limited	Sustained pulsewise release pharmaceutical preparation
US4755386A (en)	1986-01-22	1988-07-05	Schering Corporation	Buccal formulation
US5312325A (en)	1987-05-28	1994-05-17	Drug Delivery Systems Inc	Pulsating transdermal drug delivery system
US4968509A (en)	1987-07-27	1990-11-06	Mcneilab, Inc.	Oral sustained release acetaminophen formulation and process
US5033252A (en)	1987-12-23	1991-07-23	Entravision, Inc.	Method of packaging and sterilizing a pharmaceutical product
US5052558A (en)	1987-12-23	1991-10-01	Entravision, Inc.	Packaged pharmaceutical product
IL92966A (en)	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
PH27357A (en)	1989-09-22	1993-06-21	Fujisawa Pharmaceutical Co	Pyrazole derivatives and pharmaceutical compositions comprising the same
US5739136A (en)	1989-10-17	1998-04-14	Ellinwood, Jr.; Everett H.	Intraoral dosing method of administering medicaments
US5017381A (en)	1990-05-02	1991-05-21	Alza Corporation	Multi-unit pulsatile delivery system
US5633009A (en)	1990-11-28	1997-05-27	Sano Corporation	Transdermal administration of azapirones
ATE159426T1 (de)	1991-04-16	1997-11-15	Nippon Shinyaku Co Ltd	Verfahren zur herstellung einer festen dispersion
RU2120798C1 (ru)	1991-11-22	1998-10-27	Проктер энд Гэмбл Фармасьютикалз, Инк.	Твердая фармацевтическая композиция для перорального введения
US5229135A (en)	1991-11-22	1993-07-20	Prographarm Laboratories	Sustained release diltiazem formulation
US5340591A (en)	1992-01-24	1994-08-23	Fujisawa Pharmaceutical Co., Ltd.	Method of producing a solid dispersion of the sparingly water-soluble drug, nilvadipine
US5461140A (en)	1992-04-30	1995-10-24	Pharmaceutical Delivery Systems	Bioerodible polymers for solid controlled release pharmaceutical compositions
US5260068A (en)	1992-05-04	1993-11-09	Anda Sr Pharmaceuticals Inc.	Multiparticulate pulsatile drug delivery system
US5281420A (en)	1992-05-19	1994-01-25	The Procter & Gamble Company	Solid dispersion compositions of tebufelone
US5323907A (en)	1992-06-23	1994-06-28	Multi-Comp, Inc.	Child resistant package assembly for dispensing pharmaceutical medications
AU4198793A (en)	1992-07-24	1994-01-27	Takeda Chemical Industries Ltd.	Microparticle preparation and production thereof
US5700485A (en)	1992-09-10	1997-12-23	Children's Medical Center Corporation	Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
KR100291362B1 (ko)	1992-10-16	2001-09-17	니뽄 신야쿠 가부시키가이샤	왁스매트릭스의제법
KR950704727A (ko) *	1992-11-23	1995-11-20	알렌 제이, 스피겔	4-클로로-2-티오펜카복실산의 위치선택적 제조 방법(regioselective synthesis of 4-chloro-2-thiophenecarboxylic acid)
US5260069A (en)	1992-11-27	1993-11-09	Anda Sr Pharmaceuticals Inc.	Pulsatile particles drug delivery system
US5604260A (en)	1992-12-11	1997-02-18	Merck Frosst Canada Inc.	5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2
EP0759432A1 (en)	1993-01-15	1997-02-26	G.D. Searle & Co.	Use of medicaments containing 3,4-diaryl furans and analogs thereof for treating a skin-related condition
US5686105A (en)	1993-10-19	1997-11-11	The Procter & Gamble Company	Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US5409944A (en)	1993-03-12	1995-04-25	Merck Frosst Canada, Inc.	Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase
US5380738A (en)	1993-05-21	1995-01-10	Monsanto Company	2-substituted oxazoles further substituted by 4-fluorophenyl and 4-methylsulfonylphenyl as antiinflammatory agents
GB9602877D0 (en)	1996-02-13	1996-04-10	Merck Frosst Canada Inc	3,4-Diaryl-2-hydroxy-2,5- dihydrofurans as prodrugs to cox-2 inhibitors
US5436265A (en)	1993-11-12	1995-07-25	Merck Frosst Canada, Inc.	1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents
US5474995A (en)	1993-06-24	1995-12-12	Merck Frosst Canada, Inc.	Phenyl heterocycles as cox-2 inhibitors
US5344991A (en)	1993-10-29	1994-09-06	G.D. Searle & Co.	1,2 diarylcyclopentenyl compounds for the treatment of inflammation
US5466823A (en)	1993-11-30	1995-11-14	G.D. Searle & Co.	Substituted pyrazolyl benzenesulfonamides
US5393790A (en)	1994-02-10	1995-02-28	G.D. Searle & Co.	Substituted spiro compounds for the treatment of inflammation
US5665378A (en)	1994-09-30	1997-09-09	Davis; Roosevelt	Transdermal therapeutic formulation
US5633272A (en)	1995-02-13	1997-05-27	Talley; John J.	Substituted isoxazoles for the treatment of inflammation
US5567441A (en)	1995-03-24	1996-10-22	Andrx Pharmaceuticals Inc.	Diltiazem controlled release formulation
EP0827402A2 (en)	1995-05-17	1998-03-11	Cedars-Sinai Medical Center	Compositions containing fatty acids for improving digestion and absorption in the small intestine
SE9502244D0 (sv)	1995-06-20	1995-06-20	Bioglan Ab	A composition and a process for the preparation thereof
US6020343A (en)	1995-10-13	2000-02-01	Merck Frosst Canada, Inc.	(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors
GB9523946D0 (en)	1995-11-23	1996-01-24	Bayer Ag	Leukotriene antagonistic benzoic acid derivatives
US5837284A (en)	1995-12-04	1998-11-17	Mehta; Atul M.	Delivery of multiple doses of medications
US6323227B1 (en)	1996-01-02	2001-11-27	Aventis Pharmaceuticals Products Inc.	Substituted N-[(aminoiminomethyl or aminomethyl)phenyl]propyl amides
US5858401A (en)	1996-01-22	1999-01-12	Sidmak Laboratories, Inc.	Pharmaceutical composition for cyclosporines
US6929801B2 (en)	1996-02-19	2005-08-16	Acrux Dds Pty Ltd	Transdermal delivery of antiparkinson agents
US6923983B2 (en)	1996-02-19	2005-08-02	Acrux Dds Pty Ltd	Transdermal delivery of hormones
DK1288206T3 (da)	1996-04-12	2008-11-24	Searle Llc	Substituerede benzensulfonamidderivater som prolægemidler af COX-2-inhibitorer
US5861419A (en)	1996-07-18	1999-01-19	Merck Frosst Canad, Inc.	Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6458373B1 (en)	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US5840329A (en)	1997-05-15	1998-11-24	Bioadvances Llc	Pulsatile drug delivery system
US6037340A (en) *	1997-05-28	2000-03-14	Cadus Pharmaceutical Corporation	Synthesis and use of thiophene- and pyrrole-based heteroaromatic compounds
US6391452B1 (en)	1997-07-18	2002-05-21	Bayer Corporation	Compositions for nasal drug delivery, methods of making same, and methods of removing residual solvent from pharmaceutical preparations
US5869090A (en)	1998-01-20	1999-02-09	Rosenbaum; Jerry	Transdermal delivery of dehydroepiandrosterone
US6946144B1 (en)	1998-07-08	2005-09-20	Oryxe	Transdermal delivery system
DE60039379D1 (de)	1999-02-10	2008-08-21	Pfizer Prod Inc	Pharmazeutische feste Dispersionen
US6395300B1 (en)	1999-05-27	2002-05-28	Acusphere, Inc.	Porous drug matrices and methods of manufacture thereof
US6803375B1 (en) *	2000-01-06	2004-10-12	The Regents Of The University Of California	Non-peptide inhibition of T-lymphocyte activation and therapies related thereto
US6313138B1 (en)	2000-02-25	2001-11-06	Merck & Co., Inc.	Tyrosine kinase inhibitors
CA2406271A1 (en)	2000-04-18	2001-10-25	Cytovia, Inc.	Substituted 1,4-thiazepine and analogs and their use as activators of caspases
WO2002030976A1 (en)	2000-10-11	2002-04-18	The University Of Melbourne	Cell control nucleic acids and proteins
DE10061876A1 (de) *	2000-12-12	2002-06-20	Aventis Pharma Gmbh	Arylierte Furan- und Thiophencarbonsäureamide, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament sowie sie enthaltende pharmazeutische Zubereitungen
US6465014B1 (en)	2001-03-21	2002-10-15	Isp Investments Inc.	pH-dependent sustained release, drug-delivery composition
EA006769B1 (ru)	2001-08-06	2006-04-28	Фармация Италия С.П.А.	Производные аминоизоксазола в качестве ингибиторов киназы
US6960563B2 (en)	2001-08-31	2005-11-01	Morton Grove Pharmaceuticals, Inc.	Spontaneous emulsions containing cyclosporine
US6919359B2 (en)	2001-11-08	2005-07-19	Pfizer Inc	Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
AR040123A1 (es)	2002-05-31	2005-03-16	Upjohn Co	Compuestos tiofeno, antihelminticos e insecticidas
US7041690B2 (en)	2002-07-01	2006-05-09	Pharmacia & Upjohn Company, Llc	Inhibitors of HCV NS5B polymerase
JP4818726B2 (ja)	2002-10-16	2011-11-16	プロミクス・プロプライエタリー・リミテッド	炎症性腸疾患の治療
JP2006514684A (ja)	2002-10-30	2006-05-11	バーテックス　ファーマシューティカルズ　インコーポレイテッド	Ｒｏｃｋおよび他のプロテインキナーゼとして有用な組成物
US7645588B2 (en)	2003-03-04	2010-01-12	Calcimedica, Inc.	Composition comprising a cell comprising a STIM1 protein and an agent that modulates intracellular calcium and methods of use
ATE537825T1 (de)	2003-05-19	2012-01-15	Irm Llc	Immunosuppressive verbindungen und zusammensetzungen
AU2003902851A0 (en)	2003-06-06	2003-06-26	Australian Ballet School	Ballet shoe insert
TWI332832B (en)	2003-07-23	2010-11-11	Synta Pharmaceuticals Corp	Method for modulating calcium ion-release-activated calcium ion channels
US20050085531A1 (en) *	2003-10-03	2005-04-21	Hodge Carl N.	Thiophene-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof
US20050227929A1 (en)	2003-11-13	2005-10-13	Masferrer Jaime L	Combination therapy comprising a Cox-2 inhibitor and an antineoplastic agent
WO2006093518A2 (en)	2004-06-25	2006-09-08	Apath, Llc	Thienyl compounds for treating virus-related conditions
US20060223812A1 (en) *	2004-07-17	2006-10-05	Max-Planck-Gesellschaft Zur Forderungder Wissenschaften, E.V.	Treating neurodegenerative conditions
WO2006007864A1 (en) *	2004-07-17	2006-01-26	Max Planck Geselllschaft Zur Förderung Der Wissenschaft	Treating neurodegenerative conditions
PT1773768T (pt)	2004-07-30	2018-11-30	Exelixis Inc	Derivados de pirrol como agentes farmacêuticos
WO2006034402A2 (en)	2004-09-21	2006-03-30	Synta Pharmaceutical Corp.	Compounds for inflammation and immune-related uses
KR20070107022A (ko)	2005-01-07	2007-11-06	신타 파마슈티칼스 코프.	염증 및 면역 관련 용도를 위한 화합물
US8802721B2 (en)	2005-01-25	2014-08-12	Synta Pharmaceuticals Corp.	Thiophene compounds for inflammation and immune-related uses
ES2567853T3 (es)	2005-01-25	2016-04-26	Synta Pharmaceuticals Corporation	Compuestos contra la inflamación y utilizaciones relacionadas con el sistema inmunitario
EP1919882A2 (en)	2005-02-17	2008-05-14	Synta Pharmaceuticals Corporation	Isoxazole combretastatin derivatives for the treatment of proliferative disorders
US7563813B2 (en)	2005-05-13	2009-07-21	Wyeth	Iminothiazolidinone derivatives as SFRP-1 antagonists
GB0516379D0 (en)	2005-08-09	2005-09-14	Glaxo Group Ltd	Compounds
EP1754483A1 (en)	2005-08-18	2007-02-21	Merck Sante	Use of thienopyridone derivatives as AMPK activators and pharmaceutical compositions containing them
US8399185B2 (en)	2006-01-05	2013-03-19	Immune Disease Institute, Inc.	Regulators of NFAT
WO2007083689A1 (ja)	2006-01-19	2007-07-26	Renascience Co., Ltd.	プラスミノーゲンアクチベーターインヒビター－１阻害剤
JP2009524677A (ja)	2006-01-25	2009-07-02	シンタファーマシューティカルズコーポレーション	炎症および免疫関連使用用のチアゾールおよびチアジアゾール化合物
US20070275960A1 (en)	2006-01-25	2007-11-29	Synta Pharmaceuticals Corp.	Phenyl and pyridyl compounds for inflammation and immune-related uses
US8741960B2 (en)	2006-01-25	2014-06-03	Synta Pharmaceuticals Corp.	Substituted aromatic compounds for inflammation and immune-related uses
CA2640091A1 (en)	2006-01-25	2007-08-02	Synta Pharmaceuticals Corp.	Vinyl-phenyl derivatives for inflammation and immune-related uses
TW200806290A (en)	2006-01-25	2008-02-01	Synta Pharmaceuticals Corp	Substituted biaryl compounds for inflammation and immune-related uses
JP5430944B2 (ja)	2006-01-31	2014-03-05	シンタファーマシューティカルズコーポレーション	炎症および免疫関連用途のためのピリジルフェニル化合物
AU2007227210A1 (en)	2006-03-20	2007-09-27	Synta Pharmaceuticals Corp.	Benzoimidazolyl-parazine compounds for inflammation and immune-related uses
US8163777B2 (en)	2006-03-23	2012-04-24	Synta Pharmaceuticals Corp.	Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
EP2086326B1 (en)	2006-11-13	2014-01-08	Synta Pharmaceuticals Corp.	Cyclohexenyl-aryl compounds for inflammation and immune-related uses
WO2008122038A1 (en)	2007-04-02	2008-10-09	President And Fellows Of Harvard College	Regulating autophagy
WO2008148108A1 (en) *	2007-05-24	2008-12-04	Calcimedica, Inc.	Calcium channel proteins and uses thereof
WO2009001214A2 (en) *	2007-06-28	2008-12-31	Pfizer Products Inc.	Thieno[2,3-d]pyrimidin-4(3h)-one, isoxazolo[5,4-d]pyrimidin-4(5h)-one and isothiazolo[5,4-d]pyrimidin-4(5h)-one derivatives as calcium receptor antagonists
WO2009011850A2 (en) *	2007-07-16	2009-01-22	Abbott Laboratories	Novel therapeutic compounds
JP5411141B2 (ja)	2007-09-10	2014-02-12	カルシメディカ，インク．	細胞内カルシウムを調節する化合物
WO2009076454A2 (en)	2007-12-12	2009-06-18	Calcimedica, Inc.	Compounds that modulate intracellular calcium
US7981925B2 (en)	2008-08-27	2011-07-19	Calcimedica, Inc.	Compounds that modulate intracellular calcium
JP4879240B2 (ja)	2008-09-16	2012-02-22	株式会社リコー	発振回路、ｄｃ−ｄｃコンバータ及び半導体装置
US8524763B2 (en)	2008-09-22	2013-09-03	Calcimedica, Inc.	Inhibitors of store operated calcium release

2008
- 2008-08-15 JP JP2010524085A patent/JP5411141B2/ja not_active Expired - Fee Related
- 2008-08-15 BR BRPI0816326 patent/BRPI0816326A2/pt not_active IP Right Cessation
- 2008-08-15 WO PCT/US2008/073392 patent/WO2009035818A1/en not_active Ceased
- 2008-08-15 AU AU2008299220A patent/AU2008299220B2/en not_active Ceased
- 2008-08-15 CA CA2699157A patent/CA2699157A1/en not_active Abandoned
- 2008-08-15 MX MX2010002712A patent/MX2010002712A/es not_active Application Discontinuation
- 2008-08-15 EP EP08798036A patent/EP2200607A4/en not_active Withdrawn
- 2008-08-15 RU RU2010112967/04A patent/RU2465272C2/ru not_active IP Right Cessation
- 2008-08-15 US US12/192,812 patent/US8263641B2/en not_active Expired - Fee Related
- 2008-08-15 CN CN200880115726A patent/CN101854933A/zh active Pending
- 2008-08-15 KR KR1020107007759A patent/KR101257550B1/ko not_active Expired - Fee Related
2012
- 2012-07-19 US US13/553,726 patent/US8524765B2/en active Active

Also Published As

Publication number	Publication date
US20090137659A1 (en)	2009-05-28
MX2010002712A (es)	2010-06-09
US8524765B2 (en)	2013-09-03
AU2008299220A1 (en)	2009-03-19
WO2009035818A8 (en)	2009-05-14
EP2200607A1 (en)	2010-06-30
KR20100061836A (ko)	2010-06-09
CA2699157A1 (en)	2009-03-19
KR101257550B1 (ko)	2013-04-24
RU2010112967A (ru)	2011-10-20
AU2008299220B2 (en)	2011-07-21
JP5411141B2 (ja)	2014-02-12
JP2010539083A (ja)	2010-12-16
US20120289587A1 (en)	2012-11-15
US8263641B2 (en)	2012-09-11
CN101854933A (zh)	2010-10-06
EP2200607A4 (en)	2012-02-22
WO2009035818A1 (en)	2009-03-19
RU2465272C2 (ru)	2012-10-27

Publication	Publication Date	Title
BRPI0816326A2 (pt)	2015-03-24	Compostos que modulam cálcio intracelular
ZA201101335B (en)	2011-10-26	Compounds that modulate intracellular calcium
NL300962I2 (nl)	2020-06-02	patiromer sorbitex calcium
BRPI0919024A2 (pt)	2019-09-24	compostos que seletivamente modulam o receptor cb2
BRPI0819093A2 (pt)	2017-05-02	compostos moduladores de sirtuína
BRPI0813653A2 (pt)	2014-12-30	Compostos de imidazotiazol moduladores de sirtuína
BRPI0813651A2 (pt)	2014-12-30	Compostos de tiazolopiridina moduladores de sirtuína
BRPI1011668A2 (pt)	2016-03-22	compostos que modulam seletivamente o receptor cb2
DK2185567T3 (da)	2011-05-16	Substituerede bicyclolactam-forbindelser
BRPI0812131A2 (pt)	2014-11-18	Embalagem de sutura
BRPI0810362A2 (pt)	2014-10-29	Compostos de morfolinila deuterados
BRPI0813500A2 (pt)	2015-01-06	Compostos antivirais
PL2563776T3 (pl)	2017-01-31	Związki, które modulują wewnątrzkomórkowy wapń
BRPI0821086A2 (pt)	2014-10-07	Compostos inseticidas
BRPI0821831A2 (pt)	2015-06-16	Compostos inseticidas
BRPI0820372A2 (pt)	2015-05-12	Compostos herbicidas
BRPI0818253A2 (pt)	2015-04-07	Moduladores de gpr40 bifenil substituídos
BRPI0815042A2 (pt)	2015-02-10	Compostos de pirazol
EP2609095A4 (en)	2014-06-18	COMPOUNDS MODULATING INTRACELLULAR CALCIUM
BRPI0811264A2 (pt)	2014-11-04	Compostos
EP2563759A4 (en)	2013-10-23	Compounds that modulate intracellular calcium
BRPI0809996A2 (pt)	2014-10-14	Compostos
BRPI0814424A2 (pt)	2015-01-06	Compostos heterociclila
EP2477982A4 (en)	2013-04-03	COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM
BRPI0922098A2 (pt)	2015-12-15	composto inorgânicos

Legal Events

Date	Code	Title	Description
2016-09-20	B08F	Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]	Free format text: REFERENTE A 8A ANUIDADE.
2017-01-17	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.